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Abstract
The purpose of this study was to conduct a two-stage case control association study including 654 acute myeloid
leukaemia (AML) patients and 3477 controls ascertained through the NuCLEAR consortium to evaluate the effect of 27
immune-related single nucleotide polymorphisms (SNPs) on AML risk. In a pooled analysis of cohort studies, we found
that carriers of the IL13rs1295686A/A genotype had an increased risk of AML (PCorr= 0.0144) whereas carriers of the
VEGFArs25648T allele had a decreased risk of developing the disease (PCorr= 0.00086). In addition, we found an
association of the IL8rs2227307 SNP with a decreased risk of developing AML that remained marginally significant after
multiple testing (PCorr= 0.072). Functional experiments suggested that the effect of the IL13rs1295686 SNP on AML risk
might be explained by its role in regulating IL1Ra secretion that modulates AML blast proliferation. Likewise, the
protective effect of the IL8rs2227307 SNP might be mediated by TLR2-mediated immune responses that affect AML blast
viability, proliferation and chemorresistance. Despite the potential interest of these results, additional functional studies
are still warranted to unravel the mechanisms by which these variants modulate the risk of AML. These findings
suggested that IL13, VEGFA and IL8 SNPs play a role in modulating AML risk.
Introduction
Acute Myeloid Leukaemia (AML) is a common hae-
matological malignancy characterised by the clonal
transformation of haematopoietic precursors that alter
normal hematopoietic cell growth and differentiation1.
Epidemiological studies suggested that AML onset can be
triggered by multiple factors including age, sex, lifestyle,
exposure to chemicals and a number of blood and con-
genital disorders2. However, the biological mechanisms
underlying AML aetiology remain largely elusive. Even
though cytogenetic analysis have allowed the stratification
of AML patients into favourable, intermediate and unfa-
vourable classes and has improved our ability to predict
clonal evolution and disease progression3, many AML
patients (~ 45%) have a normal karyotype, which suggests
that additional genetic alterations are needed to develop
the disease. Sequencing studies identified genes frequently
mutated in AML, some of which predict poor prognosis
(NPM1wt/FLT3-ITDhigh, RUNX1, ASXL1 and TP53)4.
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Furthermore, it is increasingly evident that host immunity
might also be implicated in AML risk and survival5. AML
blasts activate immunosuppressive mechanisms to evade
the immune system whereas immune response changes
induced by the gut microbiota can also influence the anti-
leukaemic effects of immune cells6. In addition, the effi-
cacy of allogeneic stem cell transplantation (SCT) in
eradicating AML is linked to the appearance of the graft-
versus-leukaemia effect, mediated by the recognition of
major histocompatibility antigens present in malignant
blasts by T cells7. Likewise, the disappearance of these
circulating T cells recognising AML or the loss of costi-
mulatory (CD28/CD80, ICAM-1/CD11a) or inhibitory
interactions (PD-1/PDL-1) eventually leads to relapse8
and the infusion of donor-derived CD8+ memory T cells
induces remission in patients who relapsed following
allogeneic SCT9. Considering that around two-thirds of
AML patients relapse within the first 18 months after
first-line therapy, clinical trials are trying to assess the
efficacy of immunotherapies in AML and to unravel the
interplay between the immune system and AML blasts.
Considering the aspects detailed above, the purpose of
this study was to conduct a two-stage case control asso-
ciation study including 654 AML patients and 3477
controls ascertained through the NuCLEAR consortium
to evaluate whether 27 single nucleotide polymorphisms
(SNPs) within the IL4, IL8, IL8RB (CXCR2), IL12A, IL12B,
IL13, IFNG, IFNGR2, CCR5, MIF and VEGFA loci influ-
ence the risk of developing AML. We also decided to
investigate the correlation of selected SNPs with serum
steroid hormone levels and their role in modulating
immune responses after stimulation of whole blood,
peripheral mononuclear cells (PBMCs) and macrophages
with lipopolysaccharide (LPS), phytohemagglutinin
(PHA), Pam3Cys and CpG.
Material, subjects and methods
Study design and study populations
We conducted a two-stage genetic association study to
assess whether 27 functional single nucleotide poly-
morphisms (SNPs) within host immunity-related genes
could influence AML risk. The discovery population
consisted of 2027 European subjects (338 AML patients
and 1689 healthy controls). AML patients were diagnosed
by experienced clinicians and ascertained through the
iNternational Consortium for LEukaemiA Research
(NuCLEAR; Table 1). A set of AML patients were
recruited from 2 Spanish medical institutions (Virgen de
las Nieves University Hospital, Granada and Hospital of
Salamanca, Salamanca), the University of Würzburg
(Würzburg, Germany) and the University of Innsbruck
(Innsbruck, Austria)10. Healthy controls included 667
Spanish blood donors from the REPAIR consortium11,
1000 German controls came from the Heinz-Nixdorf
Recall (HNR) study12 and 22 donors of allogeneic stem
cell transplantation from the Medical University of
Innsbruck (Innsbruck, Austria). In accordance with the
Declaration of Helsinki, all study participants provided
their written informed consent to participate in the study
and the ethical committees of all participating centres and
hospitals approved the study.
DNA extraction, SNP selection criteria and genotyping
Genomic DNA from all individuals was extracted from
saliva or blood samples using the Oragen®-DNA Self-
Collection kit (Oragene) or the Maxwell® 16 Blood DNA
Purification kit (Promega) according to manufacturer’s
instructions. SNP selection criteria were based on previous
associations with haematological malignancies (AML, ALL,
CML, CLL and non-Hodgkin lymphomas) or solid tumours
and clinical related parameters (graft versus host disease,
whole blood leucocyte counts, anthropometric measures,
etc.) but also according to their functionality in Haploreg
(https://pubs.broadinstitute.org/mammals/haploreg/
haploreg.php), Regulome (https://www.regulomedb.org/
Table 1 Demographic and clinical characteristics of AML

























Age (years) 55.19 ± 15.12 56.91 ± 17.25 56.02 ± 16.20
Sex ratio
(male/female)
1.13 (179/159) 1.29 (178/138) 1.20 (356/297)
Country of origin
Spain 257 97 354
Germany 26 74 100
Italy – 145 145
Austria 55 – 55
Presentation
de novo (n, %) 324 (95.86) 285 (90.19) 609 (93.12)
Secondary (n, %) 14 (04.14) 31 (09.81) 45 (06.88)
Healthy controls
Age (years)* 56.10 ± 9.55 42.76 ± 11.76 49.57 ± 11.33
Sex ratio
(male/female)
1.07 (871/818) 0.91 (848/937) 0.98 (1719/1754)
Country of origin
Spain 667 507 1174
Germany 1000 1087 2087
Italy – 194 194
Austria 22 – 22
Data are means ± standard deviation or percentage (%). A set of 99 patients (39
and 61 from the discovery and replication cohorts, respectively) could not be
classified according to the FAB classification.
AML acute myeloid leukaemia
*Age was not available in a set of German controls included in the discovery
(n= 1000) and replication cohorts (n= 1068).
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regulome-search/), Blood eQTL browsers (https://gene-
network.nl/bloodeqtlbrowser/ and https://gtexportal.org/
home/index.html), and linkage disequilibrium values (Table
2 and Supplementary Fig. 1). Genotyping was performed
using KASP® probes (LGC Genomics, Hoddesdon, UK)
according to previously reported protocols13. For quality
control, ∼5% of DNA samples were randomly included as
duplicates and concordance between duplicate samples was
≥99.0%. AML cases and controls were randomly distributed
in 384-well plates and the person doing genotyping
experiments did not know how AML cases and controls
were distributed.
Statistical analysis
Deviation from Hardy-Weinberg Equilibrium (HWE)
was tested in the controls by chi-square (χ2). Logistic
regression adjusted for sex and country of origin was used
to assess the associations of the SNPs with AML risk
assuming log-additive, dominant and recessive models.
According the Meff method
14, 24 of 27 SNPs were inde-
pendent and, consequently, the study-wide significant
threshold was set to 0.0007 (0.05/24SNPs/3models). Sta-
tistical power was calculated using Quanto (v.12.4)
assuming a log-additive model of inheritance.
Replication cohort
For replication purposes, the most relevant findings
(P < 0.05) were replicated in a cohort of 2104 subjects (316
AML cases and 1788 healthy controls). AML cases were
recruited from an independent Spanish medical institu-
tion (Hospital General of Valencia, Valencia, Spain), from
the University Hospital of Würzburg (Germany) and from
two Italian medical institutions (Università Cattolica del
Sacro Cuore, Rome and University of Modena and Reggio
Emilia, AOU Policlinico, Modena) between 2015 and
2017. Five hundred and seven Spanish controls were
blood donors recruited from the Blood Transfusion
Centre (CRTS, Granada-Almería), 194 Italian controls
from the REPAIR consortium, 1068 German controls
from a second and independent set of the Heinz-Nixdorf
Recall (HNR) study (University Hospital of Essen) and 19
donors of allogeneic stem cell transplantation from the
University of Würzburg (Germany). The ethical com-
mittees of these centres approved the study.
Functional analysis of the host immune-related variants
In order to determine the biological function of the
most relevant SNPs, cytokine production in response to
stimulation was measured in the 500 Functional Geno-
mics cohort from the Human Functional Genomics Pro-
ject (HFGP; http://www.humanfunctionalgenomics.org/).
The Arnhem-Nijmegen Ethical Committee approved
the study (42561.091.12) and biological specimens were
collected after informed consent was obtained. We
investigated whether any SNP was correlated with cyto-
kine levels (IFNγ, IL1Ra, IL1β, IL6, IL8, IL10, TNFα, IL17,
and IL22) after stimulation of peripheral blood mono-
nuclear cells (PBMCs), whole blood or monocyte-derived
macrophages from 408 healthy subjects with LPS (1 or
100 ng/ml), PHA (10 μg/ml), Pam3Cys (10 μg/ml), and
CpG (100 ng/ml). After log transformation, linear
regression analyses adjusted for age and sex were used to
determine the correlation of selected SNPs with cytokine
expression quantitative trait loci (cQTLs). All analyses
were performed using R software (www.r-project.org/). In
order to account for multiple comparisons, we used a
significant threshold of 0.00006, i.e., the quotient of 0.05/
(24 independent SNPs × 9 cytokines × 4 cell stimulants).
Detailed protocols for PBMCs isolation, macrophage
differentiation and stimulation assays have been reported
elsewhere15–17. Briefly, PBMCs were washed twice in
saline and suspended in medium (RPMI 1640) supple-
mented with gentamicin (10 mg/ml), L-glutamine
(10 mM) and pyruvate (10 mM). PBMC stimulations were
performed with 5×105 cells/well in round-bottom 96-
wells plates (Greiner) for 24 h in the presence of 10%
human pool serum at 37 °C and 5% CO2. Supernatants
were collected and stored in −20 °C until used for ELISA.
LPS (100 ng/ml), PHA (10μg/ml) and Pam3Cys (10 μg/
ml) and CpG (100 ng/ml) were used as stimulators for 24
or 48 h. Whole blood stimulation experiments were
conducted using 100 μl of heparin blood that was added
to a 48 well plate and subsequently stimulated with 400 μl
of LPS and PHA (final volume 500ul) for 48 h at 37 °C and
5% CO2. Supernatants were collected and stored in
−20 °C until used for ELISA. Concentrations of human
TNFα, IFNγ, IL1β, IL1RA, IL6, IL8, IL10, IL17, and IL22
were determined using specific commercial ELISA kits
(PeliKine Compact, Amsterdam, or R&D Systems), in
accordance with the manufacturer’s instructions.
Correlation between steroid hormone levels and
immunoregulatory SNPs
Given the impact of steroid hormones in modulating
immune responses, we also evaluated the correlation of
SNPs with serum levels of 7 steroid hormones (andros-
tenedione, cortisol, 11-deoxy-cortisol, 17-hydroxy pro-
gesterone, progesterone, testosterone and 25 hydroxy
vitamin D3) in a subset of subjects without hormonal
replacement therapy or oral contraceptives (n= 280).
Complete protocol details have been reported else-
where17. Steroid hormones were analysed by liquid
chromatography tandem–mass spectrometry (LC–MS)
after protein precipitation and solid-phase extraction as
described in Ter Horst et al.17 (see also Supplementary
Material). Hormone levels and genotyping data were
available for a total of 406 subjects. After log transfor-
mation, correlation between SNPs and serum steroid
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hormone levels was evaluated using linear regression
adjusted for age and sex in R (http://www.r-project.org/).
Significance thresholds were set to 0.0003 (0.05/24 inde-
pendent SNPs/7 hormones).
Results
This study was conducted in a discovery population
comprised of 338 AML patients and 1689 healthy con-
trols. AML patients had a similar age than controls (55.19
±15.12 vs. 56.91±17.25) and showed a slightly increased
male/female ratio compared to healthy controls (1.13
[179/159] vs. 1.07 [871/818]. Ninety five percent of the
patients had de novo AML whereas the remaining 5%
presented secondary disease evolving from a preceding
dysplasia (Table 1).
The association analysis of the discovery population
revealed that 11 immunoregulatory SNPs were associated
with AML risk (P < 0.05; Table 3). We found that carriers
of the IFNGR2rs1059293T allele or the IL4rs2243248G/G,
IL13rs20541T/T, IL13rs1295686A/A and VEGFArs998584T/T gen-
otypes showed an increased risk of developing the disease
(ORDom= 1.51, P= 0.0074; ORRec= 4.33, P= 0.012;
ORRec= 1.98, P= 0.028; ORRec= 2.16, P= 0.012; and
ORRec= 1.40, P= 0.034). In addition, we observed that
each copy of the IL4rs2243268C allele was associated with a
1.31-fold increased risk of AML (ORAdd= 1.31, P= 0.042).
On the other hand, we found that carriers of the
IL8rs2227307G and VEGFArs25648T alleles had a significantly
decreased risk of AML (ORDom= 0.70, P= 0.012 and
ORDom= 0.42, P= 0.00002) whereas each copy of the
IL8rs4073A, CCR5rs1799987G, CCR5rs2734648T alleles was asso-
ciated with ~ 20–25% decreased risk of AML (ORAdd=
0.81, P= 0.020; ORAdd= 0.82, P= 0.043 and ORAdd= 0.75,
P= 0.0044). Even though only the association of the
VEGFArs25648 SNP with a decreased risk of developing AML
remained significant after correction for multiple testing in
the discovery cohort (PCorr= 0.0014), we found that the
association of IL8rs2227307 and IL13rs1295686 with AML risk
was confirmed in the replication population (ORDom= 0.74,
P= 0.040 and ORDom= 2.24, P= 0.0051, respectively;
Table 3). The pooled analysis including 4131 subjects (654
AML cases and 3477 controls) confirmed that carriers of
the IL13rs1295686 genotype had a significantly increased risk
of AML (ORRec= 2.18, P= 0.0002, PCorr= 0.0144) whereas
carriers of the IL8rs2227307G allele had a decreased risk of
developing the disease that remained marginally significant
after correction for multiple testing (ORDom= 0.72, P=
0.0010, PCorr= 0.072). Interestingly, although it was not
statistically significant in the replication population likely
due to the relatively limited power, the pooled analysis also
revealed a strong association of the VEGFArs25648T allele
with a decreased risk of AML that largely surpassed the
stringent study-wide significant threshold (ORDom= 0.60,
P= 0.0000012, PCorr= 0.00086; Table 3).
In an effort to determine the functional relevance of these
polymorphisms, we performed in vitro stimulation
experiments in a large cohort of healthy donors to inves-
tigate whether IL8, IL13 and VEGFA SNPs could correlate
with levels of IFNγ, IL1Ra, IL1β, IL6, IL8, IL10, TNFα,
IL17, and IL22 after stimulation of PBMCs, whole blood or
monocyte-derived macrophages with LPS, PHA, Pam3Cys,
and CpG. These experimental studies revealed that carriers
of the IL8rs2227307T allele had increased levels of IL1β after
the stimulation of PBMCs with Pam3Cys (P= 0.00058;
Fig. 1a). Although this association did not survive multiple
testing correction, these results suggested that this variant
might have an impact on AML risk through the modula-
tion of TLR2-immune responses. In support of a functional
role of the IL8rs2227307 SNP in AML, it has been also
reported that this SNP represents an eQTL for PF4V
(Fig. 1b), a locus involved in chemokine-mediated immune
responses. Interestingly, although it neither reached sta-
tistical significance after multiple testing correction, we also
found a negative correlation between the IL13rs1295686A
allele and levels of IL1Ra after stimulation of PBMCs with
LPS (P= 0.002; Fig. 1c), which suggested that the IL13
locus might play a role in the pathogenesis of AML likely
through the modulation of IL1Ra-mediated immune
responses. No correlation between selected SNPs and
serum steroid hormone levels was found suggesting that
the functional effect of these markers on the immune
responses was not mediated by steroid hormones.
Discussion
AML has been the object of investigations that have
demonstrated that host immunity contributes to disease
susceptibility. This study reports for the first time an
association of the IL13rs1295686, IL8rs2227307, and VEG-
FArs25648 polymorphisms with AML risk. The association
of the IL13 and VEGFA SNPs with AML risk remained
significant after multiple testing correction, whereas the
association of IL8rs2227307 was not significant but close to
the multiple testing significance threshold. These results
suggested that the IL13, VEGFA and IL8 loci might be
susceptibility markers for AML.
The IL13 gene is located on chromosome 5q31 and
encodes for IL13, an immunoregulatory cytokine with
pleiotropic functions. Several SNPs (rs20541, rs18000925
and rs1295686) within this gene have been consistently
associated, at GWAS level, with immune-related dis-
eases18,19 and haematological malignancies20. In this
two-stage case control association study we found a
consistent and statistically significant association of the
IL13rs1295686A/A genotype with an increased risk of
developing AML that suggested a role of this locus in the
pathogenesis of the disease. Mechanistically, we observed
a negative correlation between the IL13rs1295686A allele
and IL1Ra levels after stimulation of PBMCs with LPS
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(P= 0.002; Fig. 1c). Although this association did not
remain significant after correction for multiple testing,
this finding supported our genetic results suggesting a
role of the IL13rs1295686 SNP in the pathogenesis of AML.
Considering our results but also those from an early
report that demonstrated that IL1Ra levels are decreased
in AML patients compared to controls21, we hypothesise
that the effect of the IL13rs1295686A allele on AML risk
might be explained by its role in inhibiting IL1Ra secre-
tion, likely through the inhibition of IL1Ra secretion from
either AML blasts or healthy cells. In line with this
argument, it has been consistently reported that IL1Ra
inhibits AML blast proliferation22 and that it is associated
with the immunosuppressive effect of the mesenchymal
stem cells (MSCs) in the bone marrow that accounts for
macrophage polarisation (toward the M2 phenotype) and
B cell differentiation and survival23. Although at this point
it is tempting to speculate that the IL13rs1295686A allele,
which correlates with lower levels of IL1Ra secretion,
might represent a biomarker with a potential benefit in
AML by antagonising IL1 effects on blast proliferation
and blocking inflammation, we believe that additional
functional experiments are still warranted to explain the
exact mechanism by which the IL13rs1295686 variant
influence the risk of AML.
Another interesting finding of this study was the con-
sistent association of the IL8rs2227307T allele with a
decreased risk of developing AML. Although the associa-
tion of the IL8rs2227307 SNP with AML risk remained only
marginally significant after multiple testing correction, this
finding suggested that the IL8 locus might play a role in
the pathogenesis of AML. The IL8 gene is located on
chromosome 4q12-q21 and encodes for IL8, a chemokine
mainly produced by macrophages and epithelial cells.
Previous studies have suggested that the blocking IL8-
CXCR2 pathway might have a therapeutic potential in a
variety of tumours24–27 including AML and myelodys-
plastic syndromes (MDS)28. However, the role of IL8 in
AML is still scarce. A recent study has demonstrated that
IL8 and its receptor are significantly overexpressed in
Fig. 1 Functional impact of the IL8rs2227307 SNP on immune responses. Correlation between the IL8rs2227307 SNP and IL1β levels after stimulation
of PBMCs (n=408) with Pam3Cys (10μg/ml) (a) or PF4V expression in peripheral blood (b) and correlation between the IL13rs1295686 SNP with IL1Ra
levels after stimulation of PBMCs with LPS (100ng/ml) (c). Gene expression plot from the GTEx portal; https://gtexportal.org/home/index.html).
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AML and MDS patients28 and that the expression of these
molecules also correlates with poor outcomes. In addition,
it has been reported that the IL8-CXCR2 axis is highly
expressed in hematopoietic stem cells and progenitor
compartments in comparison with healthy controls28 and
that this pathway plays a key role in the regulation of cancer
stem cell function29–31 and mesenchymal stem cell-induced
T cell proliferation. In addition, Schinke et al. (2015) have
experimentally demonstrated that the inhibition of CXCR2
leads to decreased viability and clonogenic capacity of pri-
mary cells from AML patients, which pointed towards the
use of IL8-CXCR2 pathway as novel therapeutic target28. In
line with our genetic data and the notion of a role of the IL8
locus in the pathogenesis of AML, we found that carriers of
the IL8rs2227307T allele had increased levels of IL1β after the
stimulation of PBMCs with Pam3Cys (P= 0.00058; Fig. 1a).
These results suggested that the protective effect of the
IL8rs2227307 SNP on AML risk might be mediated by TLR2-
induced immune responses that are initially regulating IL1β
secretion and, subsequently, IL8 production in a wide range
of pathological conditions32–35. Given that the correlation
of the IL8rs2227307 SNP with increased levels of IL1β did not
reach the significance threshold after correction for multi-
ple testing, we need to interpret these results with caution.
Nonetheless, it worth mentioning that they were in agree-
ment with previous studies showing that TLRs are
expressed in multiple AML cell lines and primary AML
samples36 and that stimulation of TLR2 in normal hema-
topoietic cells led to differentiation and proliferation of
hematopoietic stem cells and myeloid progenitor cells.
Furthermore, another study proposed a TLR2-binding cell-
penetrating peptide as a promising candidate for targeted
drug development in AML37. In addition to these findings,
IL8rs2227307 has been also reported to be an eQTL for PF4V
(Fig. 1b), a locus involved in chemokine-mediated immune
responses. These results suggest that the IL8rs2227307 poly-
morphism might also influence the risk of AML through
chemotaxis stimulation in the microenvironment of the
bone marrow (BM). In line with this notion, it has been
demonstrated that IL8 is a hypoxia-regulated cytokine that
promotes migration in mesenchymal stromal cells in the
BM38 and that both endogenous and hypoxia-induced
production of IL8 was higher in AML cases compared to
controls and was prognostically unfavourable38. A more
recent study has also suggested that IL8 blockade might be
used as new therapeutic strategy for AML, as it prevents
activated endothelial cell mediated proliferation and
chemoresistance39.
Finally, even though we did not find any functional effect
of the VEGFArs25648 SNP to modulate immune responses,
our genetic findings are in line with previous studies
reporting an increased vascularity and VEGFA levels in
AML patients, and a specific VEGFA-dependent vascular
morphology in the leukemic BM40. In addition, it has been
reported that VEGFA levels are an independent prognostic
factor41 and that they modulate the appearance of graft
versus host disease after SCT42. Based on the current
evidence, we hypothesize that the VEGFArs25648 SNP
might influence the risk of developing AML through
changes in BM vascularity and morphology and migration
of human leukemia cells.
One of the major strengths of our study is the inclusion of
two large populations. In the combined analysis, we had
80% power to detect an odds ratio of 1.33 (α= 0.0007) for a
SNP with a frequency of 0.25, which underlined the feasi-
bility of the study design. Another important strength of
this study is the development of cytokine stimulation
experiments and the measurement of seven serum steroid
hormones in a large cohort of healthy subjects, which
allowed us to investigate the functional role of the most
relevant markers in modulating immune responses but also
in determining serological steroid hormone levels. A
drawback is the multicentric nature of this study that placed
inevitable limitations such as the impossibility of uniformly
collect cytogenetic and mutation profiles for a significant set
of patients. Another limitation was that age was unknown
for a subset of German controls. However, given that
selected SNPs have not been linked to survival in AML, we
think that age is not a modifying factor that could sig-
nificantly influence the results.
In conclusion, we identified for the first time IL8, IL13,
and VEGFA SNPs as susceptibility biomarkers for AML
and provided new insights about the possible role of these
loci in modulating innate and adaptive immune respon-
ses, and thereby becoming potentially clinical targets for
enhancement of the antileukemic effects of immune cells.
Functional data used in this project have been meticu-
lously catalogued and archived in the BBMRI-NL data
infrastructure (https://hfgp. bbmri.nl/) using the MOL-
GENIS open source platform for scientific data43. This
allows flexible data querying and download, including
sufficiently rich metadata and interfaces for machine
processing (R statistics, REST API) and using FAIR
principles to optimise Findability, Accessibility, Inter-
operability and Reusability44.
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